Amylyx Pharmaceuticals Overview
Valuation check: AMLX's ROE is -63.59%, below the sector sector average of -6.13%.
Get informed when a big investor buys or sells
+ Follow-63.59%
Return on Equity measures how efficiently a company uses shareholders' equity to generate profits. A higher ROE indicates better profitability relative to equity.
As of the most recent data, AMLX shows a ROE of -63.59%. That is below the sector sector average of -6.13%. Scroll down for historical charts and peer comparison views.
The its sector sector average ROE is about -6.13%. Amylyx Pharmaceuticals is at -63.59%, which is lower that average. That is roughly 937.7% below the sector mean. Use the comparison chart on this page to see how AMLX stacks up against individual peers as well.
Check the historical chart to see whether AMLX's ROE is trending up or down. Improvement over multiple periods is generally more meaningful than a single strong quarter. Compare Amylyx Pharmaceuticals with peers to see if the move is company-specific or sector-wide.
Besides this return on equity page, Stockcircle has Amylyx Pharmaceuticals's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect ROE (currently -63.59%) with ownership activity and broader fundamentals.
